You are here: Industry Insights > acquisition

News List

OPEN Health acquires Spirit prnasia
August 04, 2021
OPEN Health has today announced the acquisition of North West UK-based medical communications agency Spirit.
Amgen to Acquire Teneobio for $900M contractpharma
July 29, 2021
Includes Teneobio's bispecific and multispecific antibody technologies, heavy-chain only platform and T-cell engager platform.
PerkinElmer agrees to acquire antibody maker BioLegend for $5.25bn pharmaceutical-technology
July 28, 2021
PerkinElmer has signed an agreement to acquire antibody and reagent maker BioLegend for nearly $5.25bn in cash and stock.
Cytiva and Pall Corporation investing 1.5 billion USD over two years to meet growing demand for biotechnology solutions prnasia
July 27, 2021
An ongoing strategic growth plan from Cytiva and Pall Corporation, part of the Danaher Corporation, will expand manufacturing capacity and services across geographies for global life sciences customers.
AstraZeneca concludes Alexion acquisition for $39bn pharmaceutical-technology
July 23, 2021
AstraZeneca has concluded the acquisition of US-based biopharmaceutical company Alexion Pharmaceuticals for a total consideration of $39bn or $175 per share.
PAG to acquire control of Acme Formulation expresspharma
July 23, 2021
PAG will invest approximately $145 million to acquire a controlling stake in the company.
Rossari to acquire Tristar Intermediates expresspharma
July 23, 2021
Rossari will be acquiring 100 per cent of the equity share capital of Tristar Intermediates.
AstraZeneca Completes Acquisition of Alexion americanpharmaceuticalreview
July 22, 2021
AstraZeneca completed the acquisition of Alexion Pharmaceuticals, Inc. (Alexion). The closing of the acquisition marks the Company’s entry into medicines for rare diseases and the beginning of a new chapter for AstraZeneca.
Philip Morris agrees to acquire Vectura for $1.45bn pharmaceutical-technology
July 13, 2021
Philip Morris International (PMI) has made an offer to acquire a contract development and manufacturing organisation (CDMO), Vectura Group, for approximately $1.45bn (£1.045bn) to boost its product pipeline development expertise in inhaled treatments.
AstraZeneca receives EC approval for $39bn Alexion acquisition pharmaceutical-technology
July 07, 2021
The European Commission has cleared the proposed acquisition by AstraZeneca of US-based biopharmaceutical company Alexion Pharmaceuticals for approximately $39bn or $175 a share.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 40 41 Next page